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Abstract
Trabectedin, a new antitumor compound originally derived from a marine tunicate, is clinically effective in soft tissue
sarcoma. The drug has shown a high selectivity for myxoid liposarcoma, characterized by the translocation t(12;16)(q13;
p11) leading to the expression of FUS-CHOP fusion gene. Trabectedin appears to act interfering with mechanisms of
transcription regulation. In particular, the transactivating activity of FUS-CHOP was found to be impaired by trabectedin
treatment. Even after prolonged response resistance occurs and thus it is important to elucidate the mechanisms of
resistance to trabectedin. To this end we developed and characterized a myxoid liposarcoma cell line resistant to
trabectedin (402-91/ET), obtained by exposing the parental 402-91 cell line to stepwise increases in drug concentration. The
aim of this study was to compare mRNAs, miRNAs and proteins profiles of 402-91 and 402-91/ET cells through a systems
biology approach. We identified 3,083 genes, 47 miRNAs and 336 proteins differentially expressed between 402-91 and 402-
91/ET cell lines. Interestingly three miRNAs among those differentially expressed, miR-130a, miR-21 and miR-7, harbored
CHOP binding sites in their promoter region. We used computational approaches to integrate the three regulatory layers
and to generate a molecular map describing the altered circuits in sensitive and resistant cell lines. By combining
transcriptomic and proteomic data, we reconstructed two different networks, i.e. apoptosis and cell cycle regulation, that
could play a key role in modulating trabectedin resistance. This approach highlights the central role of genes such as
CCDN1, RB1, E2F4, TNF, CDKN1C and ABL1 in both pre- and post-transcriptional regulatory network. The validation of these
results in in vivo models might be clinically relevant to stratify myxoid liposarcoma patients with different sensitivity to
trabectedin treatment.
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Introduction
Trabectedin (YondelisH) is a tetrahydroisoquinoline molecule
originally derived from the Caribbean marine tunicate, Ecteinasci-
dia turbinata, with peculiar in vitro and in vivo cytotoxic activity in a
wide range of tumor type: it has been approved by EMEA for the
second line therapy of soft tissue sarcomas and ovarian cancer [1–
7].
From a mechanistic point of view, trabectedin binds to the
minor groove of DNA, differently from the conventional alkylating
agents, forming DNA adducts on N2 position of guanine, and
bends DNA towards the major groove; two of the three fused rings
of this molecule are involved in the minor groove binding while
the third (ring C) plays an important role in the process of
interaction with different DNA-binding proteins [8,9]. It is now
widely accepted that trabectedin-DNA interaction affects tran-
scription regulation although the level of selectivity is not
completely elucidated [8,10,11].
Although trabectedin has shown activity against several types of
sarcomas, its higher activity has been observed in patients with
myxoid liposarcoma (MLS).
The high sensitivity displayed by MLS tumors is probably
correlated to the ability of trabectedin to block the aberrant
transcription activity of FUS-CHOP, the chimeric protein
hallmark of MLS, generated by the chromosomal translocation
t(12;16)(q13;p11) [12,13].
Despite its activity, it is becoming a clinical experience that
patients with long lasting trabectedin treatment develop resistance
over time. To our knowledge there are only few studies focused on
the mechanism of resistance and even fewer are based on a systems
biology approach.
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To investigate the molecular pathways involved in trabectedin
resistance, the 402-91/ET cell line, resistant to trabectedin, was
generated from the parental type I myxoid liposarcoma cell line
402-91 by stepwise increasing drug concentrations [14]. Based on
the assumption that trabectedin impairs mechanisms of transcrip-
tion regulation, we exploited several high-throughput technologies
to combine different layers of regulation to elucidate the molecular
pathways involved in the mechanism of trabectedin resistance in a
well defined in vitro model of myxoid liposarcoma, previously
described [14].
Materials and Methods
Cells and experimental design
The MLS type I 402-91 cell line was kindly supplied by Dr. P.
Aman [15], while the trabectedin resistant 402-91/ET cell line
was obtained in our laboratory as previously described [14]. For
the array experiments, different batches of exponentially growing
402-91 and 402-91/ET cells were seeded and then total RNA
enriched in microRNA (miRNA) fraction and protein lysates were
harvested according to standard protocols. Gene, miRNA and
protein expression profiles were generated from three independent
biological replicates. Each experiment was performed using four
technical replicates.
RNA purification and quantitative Reverse Transcription
PCR (qRT-PCR)
Total RNA enriched in miRNA fraction was purified using the
miRNeasy Mini Kit according to the manufacturer’s instructions
(Qiagen, Milan, Italy). RNA was quantified by spectrophotometry
(Nanodrop; Thermo Scientific, Wilmington, USA) and quality
assessed by on-chip electrophoresis (Bioanalyser RNA 6000 Nano,
Agilent Technologies, Palo Alto, USA). Mature miRNA and
mRNA expression levels were examined by qRT-PCR using
Applied Biosystems 7900HT. Briefly, cDNA was generated from
1 mg of purified total RNA using the miScriptH Reverse
Transcription Kit, following the manufacturer’s instructions
(Qiagen). miRNA expression was quantified using QuantiTect
SYBR Green PCR Master Mix and the specific miScriptH Primer
Assay (Qiagen); RU-6b was used as reference gene. mRNA
expression was analyzed using QuantiFast SYBR Green PCR
Master Mix (Qiagen) and dedicated primers that were designed as
described [16]; cyclophilin A was used as reference gene.
Experiments were run in triplicate for each case to assess technical
variability. Analysis was performed by using the 22DDCt protocol
and the median values were compared using the non parametric
Mann-Whitney t-test. Differences were considered statistically
significant with a two sided p-value,0.05. All tests and data plots
were done using GraphPad Prism Version 5.01 (GraphPad
Software, La Jolla, Ca, USA).
Western blot analysis
Total protein extracts were prepared by lysing cell extracts in
lysis buffer (50 mM Tris-HCl, pH 8.0, 1% Triton X-100,
150 mM NaCl, 1 mM EGTA, 100 mM NaF, 10% glycerol
(100%) and 1 mM MgCl2) with 2 mM phenylmethanesulfonyl
fluoride (Sigma Aldrich, St. Louis, MO) as protease inhibitor, in
agitation for 30 minutes at 4uC. Insoluble material was pelleted at
13 000 rpm at 4uC and the total protein concentration was
determined by Bradford assay. The cellular proteins (40 mg) were
separated using 8% and 15% (for detection of HMGA2 protein)
SDS-PAGE and transferred electrophoretically to polyvinylidene-
difluoride membranes (GE Healthcare, CA, USA). Blots were
probed at 4uC overnight with primary antibodies in 5% milk/Tris
Buffer Saline Tween20 (TBST). Immunoblotting was carried out
with Cyclin D1 (Pharmingen, BD, La Jolla, CA, USA- 554181),
E2F5 (abcam, Cambridge, UK - ab59769), SEMA4C (R&D
Systems, Minneapolis MN, USA – AF6125), HMGA2 (kindly
provided by Prof. Alfredo Fusco, Institute of Experimental
Endocrinology and Oncology, CNR Naples, Italy) and PDCD4
(Sigma-Aldrich – SAB1407349) antibodies. Lamin B (Santa Cruz
Biotechnology – sc6217) and Actin (Santa Cruz Biotechnology,
CA, USA– sc130301) were used for loading control. Antibody
binding was revealed by peroxidase labelled secondary antibodies
and visualized using enhanced chemiluminescent (ECL) substrate
(SuperSignal* West Pico, Thermo Scientific, Rockford IL USA).
Experiments were repeated twice.
Gene expression analysis
Gene expression (GE) was analyzed using Agilent slides on
which 44,000 oligonucleotides were spotted (Agilent Technologies,
Santa Clara, USA). Experiments were performed in four
replicates, with dye-swapping duplication-scheme. The arrays
were washed and scanned with a laser confocal scanner
(G2565BA, Agilent Technologies) according to manufacturer’s
instructions. Oligo microarrays underwent standard post hybrid-
ization processing and the intensities of fluorescence were
calculated by Feature Extraction software v.11 (Agilent Technol-
ogies). The microarray raw data are deposited in GEO
(experiment number GSE20350) according to MIAME (Minimum
Information About a Microarray Experiment) guidelines. GE
signals were filtered according to the signal-to-background flag;
features with more than 60% of signal below the local background
were removed from the analysis. Then, lowess normalization was
applied [17]. The identification of differentially expressed genes
was performed using Empirical Bayes test [18] implemented in
Bioconductor package limma in R software (http://www.r-
project.org) with Benjamini and Hochberg False Discovery Rate
(FDR) [19] to control for multiple testing problem. Given the large
number of differentially expressed genes, we decided to adopt a
more conservative strategy with respect to that applied for
differentially expressed miRNAs and proteins: FDR#0.01 and
log fold change greater/lower than 1/-1 were considered to select
differentially expressed features. Enrichment analysis of Gene
Ontology (GO) categories and KEGG pathways was performed
with DAVID web tool [20]. Cytoscape 2.7 [21] was used to
reconstruct miRNA-target network.
Transcription factor binding site enrichment analysis was
performed using oPOSSUM web tool [22].
miRNA expression analysis
100 ng of total RNA enriched in miRNA fraction was Cy5-
labelled and hybridized with a miRNA labelling and hybridization
kit according to the manufacturer’s instructions (Agilent Technol-
ogies). We used the commercially available G4470B human
miRNA microarray kit (Agilent Technologies), which consists of
15 K features printed in an 8-plex format (8 of 15 K features
printed in known human miRNAs :723 human and 76 human-
viral miRNAs) sourced from the Sanger miRBASE public
database, release 10.1. The arrays were washed and scanned
(with a laser confocal scanner) according to the manufacturer’s
instructions. miRNA microarrays underwent standard post
hybridization processing and the intensities of fluorescence were
calculated by Feature Extraction software version 11 (Agilent
Technologies). miRNA expression values were filtered as de-
scribed in the previous section, and vsn algorithm has been applied
to normalize the data [23]. miRNA data have been submitted to
Array Express (accession number E-MTAB-965).
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The identification of differentially expressed miRNAs has been
performed using Empirical Bayes test [18] implemented in
Bioconductor package limma of R software with Benjamini and
Hochberg FDR to control for multiple testing problem. FDR#0.1
were considered to select significant miRNAs.
mirandaSVR [24] was used to select putative miRNA target
genes, while integration of mRNA and miRNA data was
performed using MAGIA [25] web tool and dedicated in-house
software.
Enrichment analysis of GO categories and KEGG pathways
[26] of differentially expressed miRNA targets was performed with
DAVID web tool [20] and MetaCore software [27].
CHOP transcription factor binding site identification on
putative miRNA promoter regions was performed using miR-
Gen2.0 [28] and CircuiDB database [29]. Cytoscape 2.7 [21] was
used to reconstruct miRNA-target regulatory networks. KEGG
database has been used to retrieve gene-gene interactions.
Antibody microarray analysis
The Panorama Ab Microarray–XPRESS kit (Sigma-Aldrich)
used in this study contains 725 different antibodies, spotted in
duplicate on nitrocellulose-coated glass slides. These antibodies
represent families of proteins known to be involved in a variety of
different biological pathways (www.sigma.com/arrays). All re-
agents and solutions for protein purification were supplied within
the kit and experiment was performed on four independent
biological replicates, according to manufacturer’s instructions.
Briefly, total cell lysates were obtained from almost 10 million of
exponentially growing 402-91 and 402-91/ET cells. 10 mg of total
protein lysate, measured using Bradford protocol, were labeled
with Cy3 and Cy5 fluorescent dyes (Amersham Biosciences,
Buckinghamshire, UK) and their specific activity and concentra-
tion measured at the Nanodrop (Nanodrop, Thermo Scientific)
after affinity column purification, provided within the kit. 150 mg
of Cy3 and Cy5 labeled samples were co-hybridized on the same
slides for 459 at room temperature, accordingly to manufacturer’s
instructions. Washing and scanning (GENEPIX, version B) was
performed according to the manufacturer’s instructions. To
increase the robustness of data analysis we performed technical
replicates using dye-swap.
Scanned data files were first background subtracted using the
normexp method [30]. Positive and negative control spots were
removed, and the data were normalized using a modified rank-
invariant selection algorithm (in-vMod) [31].
Determination of differential proteins between the two cell lines
was carried out with linear models for microarray analysis [30],
correcting the resulting p-value for multiple testing with FDR. To
balance statistical significance and biological relevance, given the
relatively low number of spots on the arrays, proteins were selected
as differential expressed when their adjusted p-value was less than
or equal to 0.1, and they were subsequently annotated with the
EntrezGene and RefSeq identifiers of the corresponding genes to
facilitate data integration.
Network analysis andGO enrichment of differential proteins
was performed using the MetaCore software [27], using both
public data and internal MetaCore curated maps, and with
DAVID web tool [20]. Networks and GO terms were deemed
significant if their p-value was less than or equal to 0.1.
Results
In order to deeply understand the molecular differences
between 402-91 and 402-91/ET cells, we performed multistep
omics comparative analyses evaluating gene, miRNA and protein
expressions.
Gene expression data
A list of 2676 significant genes (corresponding to 3,083 non-
unique probes) has been identified as differentially expressed
between 402-91/ET and 402-91 cell lines (Figure 1A): 1473
(55%) underexpressed and 1203 (45%) overexpressed. Multiple
probes in the microarray platform can be representative of a single
gene; in our analysis more than 80% of probes belonging to the
same gene behave concordantly. Only 505 genes represented by
more than one probe in the platform have been identified as
significant by a single probe. The complete list of differentially
expressed probes is reported in Table S1. Remarkable is that a
significant portion of the underexpressed (6%) and of the
overexpressed (2%) genes are zinc finger proteins, i.e. proteins
able to bind DNA (p= 0.0003 with hypergeometric distribution).
Functional enrichment has been performed separately for up
and downregulated genes, both on GO categories (Table 1) and
KEGG and MetaCore pathways (Table 2).
Most of the genes overexpressed in 402-91/ET cell line are
implicated in apoptosis, regulation of cell proliferation, angiogen-
esis, vascular development and negative regulation of develop-
mental processes (enclosed the adipocyte differentiation category).
On the other hand, pathways related to metabolism, gene
expression and cell cycle progression are mainly populated by
downregulated genes. Pathways associated to cancer (p53 signaling
pathway and small cell lung cancer) are involved in trabectedin
resistance as well as immunoregulatory mechanisms like PPARs
and NOD-like receptors signaling. Some key genes involved in cell
cycle and regulation of apoptosis have been validated with qRT-
PCR (see Table S2 and section below).
miRNA expression data
Inferential analysis identified a list of 47 miRNAs that showed
an altered regulation between 402-91/ET and 402-91 cell lines
(Figure 1B): 23 overexpressed and 24 underexpressed (see Table
S3). Among these, we found two miRNA clusters (defined as
miRNAs whose chromosomal position is less than 1000 kb) on
chromosome 13 (miR-17*, miR-19a, miR-19b, miR-20a, miR-
92a) and 19 (miR-99b, let-7e, miR-125a-5p) and the miRNA
families miR-320, miR-19 and miR-29.
Moreover, we performed a functional enrichment analysis on
putative targets of significantly altered miRNAs in 402-91/ET cell
line (see Table 3). The in silico predicted targets were cleaned out
of those genes without differential expression. Gene targets of
miRNAs regulation belong to categories involved in immune
response, regulation of cell death, apoptosis and anti-apoptosis and
G1/S transition of mitotic cell cycle. Among these genes, there
were several known oncogenes playing a key role in tumor
Figure 1. Heat maps of genes and miRNAs differentially expressed between 402-91/ET and 402-91 cells. Panel A. Heat map and cluster
analysis of the 3,083 differentially expressed probes between resistant and sensitive cell lines. Red and green represent respectively differentially
upregulated and downregulated genes in 402-91/ET cell lines. Panel B. Heat map and cluster analysis of the 48 miRNA differentially expressed
between resistant and sensitive cell lines. Red and green represent respectively differentially upregulated and downregulated genes in 402-91/ET cell
lines. Gray is for missing values.
doi:10.1371/journal.pone.0035423.g001
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progression in melanoma, bladder and lung cancer. Some key
miRNAs involved in cell cycle and regulation of apoptosis have
been validated with qRT-PCR (see Table S2 and section below).
Signature validation
Apoptosis and cell cycle seem to be the most involved pathways
in trabectedin resistance in 402-91/ET cell line either on
transcriptional or on translational levels. Thus, to support the
robustness of our analysis, differences in expression of genes and
miRNA, belonging to the apoptosis and cell cycle pathways were
validate in an independent batch of 402-91 and 402-91/ET cells.
Representative results for let-7e and miR-21 are reported in
Figure 2. As expected, let-7e resulted three folds downregulated
(p,0.001) and miR-21 two folds upregulated (p,0.0001) in 402-
91/ET compared to 402-91cells. qRT-PCR analysis of let-7e
downstream targets confirmed four folds upregulation of CCDN1
(p,0.01), three folds upregulation for SEMA4C (p,0.01) and
nine folds upregulation for E2F5 (p,0.001) in the resistant
compared to the sensitive cell line (Figure 2A). Western blot
analysis confirmed at protein level such differences. Analysis of
PDCD4, a downstream target of miR-21, was confirmed to be
downregulated in the resistant cells (1.5 times, p,0.0001) at both
mRNA and protein levels (Figure 2B). These results confirmed
our omics analysis even if the effect of let-7e on HMGA2 needs to
be discussed separately. The three folds upregulation of HMGA2
at the mRNA level in 402-91/ET cells (p,0.01) was not further
confirmed by western blot analysis (Figure 2A), suggesting that
other mechanisms, not directly related to control of mRNA
stability by miR-21, are involved in the HMGA2 protein stability.
Table 1. Biological processes enrichment analysis within up and downregulated genes using Gene Ontology categories.
Category Name Adj p-value
Expression 402-91/ET vs
402-91
GO:0048522 positive regulation of cellular process 0,02 up
GO:0006915 apoptosis 0,03 up
GO:0008284 positive regulation of cell proliferation 0,04 up
GO:0031325 positive regulation of cellular metabolic process 0,04 up
GO:0051093 negative regulation of developmental process 0,05 up
GO:0001525 angiogenesis 0,05 up
GO:0001944 vasculature development 0,05 up
GO:0048523 negative regulation of cellular process 0,05 up
GO:0009893 positive regulation of metabolic process 0,05 up
GO:0001558 regulation of cell growth 0,05 up
GO:0010941 regulation of cell death 0,05 up
GO:0001501 skeletal system development 0,05 up
GO:0002684 positive regulation of immune system process 0,05 up
GO:0051249 regulation of lymphocyte activation 0,05 up
GO:0006954 inflammatory response 0,05 up
GO:0048513 organ development 0,05 up
GO:0043067 regulation of programmed cell death 0,06 up
GO:0050865 regulation of cell activation 0,06 up
GO:0051252 regulation of RNA metabolic process 0,0002 down
GO:0006350 transcription 0,0002 down
GO:0010468 regulation of gene expression 0,0006 down
GO:0080090 regulation of primary metabolic process 0,0007 down
GO:0060255 regulation of macromolecule metabolic process 0,0007 down
GO:0034645 cellular macromolecule biosynthetic process 0,0008 down
GO:0010556 regulation of macromolecule biosynthetic process 0,002 down
GO:0031326 regulation of cellular biosynthetic process 0,003 down
GO:0009889 regulation of biosynthetic process 0,003 down
GO:0051171 regulation of nitrogen compound metabolic process 0,003 down
GO:0031323 regulation of cellular metabolic process 0,003 down
GO:0019219 regulation of nucleobase. nucleoside. nucleotide and nucleic acid
metabolic process
0,003 down
GO:0009887 organ morphogenesis 0,03 down
GO:0010563 negative regulation of phosphorus metabolic process 0,03 down
GO:0000082 G1/S transition of mitotic cell cycle 0,03 down
GO:0051329 interphase of mitotic cell cycle 0,05 down
doi:10.1371/journal.pone.0035423.t001
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Table 2. Pathways enrichment analysis within up and downregulated genes using KEGG and Metacore databases.
Database Name Adj p-value
Expression 402-91/ET vs
402-91
KEGG NOD-like receptor signaling pathway 0,01 up
KEGG Small cell lung cancer 0,03 up
KEGG Vitamin B6 metabolism 0,05 up
KEGG p53 signaling pathway 0,05 up
KEGG PPAR signaling pathway 0,05 up
Metacore Immune response_IL-17 signaling pathways 0 up
Metacore Immune response_Alternative complement pathway 0 up
Metacore Cytokine production by Th17 cells in CF 0,00021 up
Metacore Cell cycle_Regulation of G1/S transition (part 1) 0,00023 up
Metacore Cell cycle_Regulation of G1/S transition (part 2) 0,0006 up
Metacore Development_TGF-beta-dependent induction of EMT via MAPK 0,0007 up
Metacore Cytokine production by Th17 cells in CF (Mouse model) 0,00085 up
Metacore Cell cycle_Nucleocytoplasmic transport of CDK/Cyclins 0,00122 up
Metacore Development_TGF-beta-dependent induction of EMT via SMADs 0,00256 up
Metacore Immune response_Th17-derived cytokines 0,00262 up
Metacore Development_PEDF signaling 0,00361 up
Metacore Cytoskeleton_Regulation of cytoskeleton rearrangement 0,00381 up
KEGG Focal adhesion 0,001 down
KEGG Notch signaling pathway 0,002 down
KEGG Prion diseases 0,003 down
KEGG ECM-receptor interaction 0,007 down
KEGG Lysosome 0,01 down
KEGG Gap junction 0,011 down
KEGG Axon guidance 0,012 down
KEGG Inositol phosphate metabolism 0,015 down
KEGG Bladder cancer 0,03 down
KEGG Tight junction 0,033 down
KEGG Neurotrophin signaling pathway 0,034 down
KEGG Insulin signaling pathway 0,035 down
KEGG Valine, leucine and isoleucine degradation 0,038 down
KEGG Chronic myeloid leukemia 0,044 down
KEGG Endocytosis 0,044 down
KEGG N-Glycan biosynthesis 0,047 down
KEGG Adherens junction 0,051 down
Metacore Cell adhesion_Amyloid proteins 0 down
Metacore Immune response_Histamine signaling in dendritic cells 0,00001 down
Metacore Signal transduction_cAMP signaling 0,00001 down
Metacore Development_S1P2 and S1P3 receptors in cell proliferation and differentiation 0,00001 down
Metacore Development_Blood vessel morphogenesis 0,00001 down
Metacore Development_Notch Signaling Pathway 0,00002 down
Metacore Development_A2A receptor signaling 0,00002 down
Metacore Blood coagulation_GPCRs in platelet aggregation 0,00002 down
Metacore Cell adhesion_Platelet aggregation 0,00002 down
Metacore Cytoskeleton_Actin filaments 0,00002 down
Metacore Development_Neurogenesis_Axonal guidance 0,00006 down
Metacore Development_A2B receptor: action via G-protein alpha s 0,00008 down
Metacore Signal transduction_Activation of PKC via G-Protein coupled receptor 0,00012 down
Metacore Transcription_CREB pathway 0,00013 down
Metacore PGE2 pathways in cancer 0,00018 down
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Antibody array data
Protein profiling identified 336 proteins that were significantly
(FDR,0.1) different between sensitive and resistant cell lines
(Table S4): 148 upregulated and 188 downregulated (see
Figure 3). Cluster dendrograms of Figure 1A, 1B and 3 were
performed on different data sources (genes, miRNAs and proteins
expression levels) characterised by different sizes, means and range
of values. Since hierarchical clusteringis highly sensitive to data
structure, some differences in dendrograms are expected, given the
intrinsic characteristics of the data. According to the experimental
design, gene, miRNA and protein expression profiles were
quantified using three different biological replicates, while within
each batch technical replicates were performed. Thus, the
difference in the dendrogram structures is due to the combination
of these effects: biological and intrinsic data differences.
In order to assess the biological meaning of the differences in the
protein expression, we performed enrichment analysis on GO
terms, cellular networks and pathway maps using DAVID web
tool and MetaCore software.
Table 2. Cont.
Database Name Adj p-value
Expression 402-91/ET vs
402-91
Metacore Signal Transduction_Cholecystokinin signaling 0,00052 down
Metacore Cytoskeleton_Regulation of cytoskeleton rearrangement 0,00105 down
Metacore Muscle contraction_Nitric oxide signaling in the cardiovascular system 0,00197 down
Metacore Development_Hedgehog signaling 0,00287 down
Metacore Cell adhesion_Leucocytechemotaxis 0,00747 down
doi:10.1371/journal.pone.0035423.t002
Table 3. GO biological processes and KEGG and Metacore pathway enrichment analysis within miRNA targets.
Category Name Adj p-value
Gene Ontology
GO:0001525 angiogenesis 0,01
GO:0000082 G1/S transition of mitotic cell cycle 0,01
GO:0043067 regulation of programmed cell death 0,02
GO:0051252 regulation of RNA metabolic process 0,02
GO:0042981 regulation of apoptosis 0,02
GO:0006355 regulation of transcription. DNA-dependent 0,02
GO:0009887 organ morphogenesis 0,02
GO:0001944 vasculature development 0,03
GO:0006916 anti-apoptosis 0,03
GO:0048705 skeletal system morphogenesis 0,03
GO:0001568 blood vessel development 0,04
GO:0046395 carboxylic acid catabolic process 0,07
GO:0048514 blood vessel morphogenesis 0,07
GO:0016477 cell migration 0,09
Pathway
Metacore PGE2 pathways in cancer 0
Metacore Immune response_Histamine signaling in dendritic cells 0,00013
Metacore Signal transduction_cAMP signaling 0,00015
Metacore Development_S1P1 receptor signaling via beta-arrestin 0,00019
Metacore Muscle contraction_Regulation of eNOS activity in endothelial cells 0,00021
Metacore Immune response_Histamine H1 receptor signaling in immune response 0,00022
Metacore Cell adhesion_Chemokines and adhesion 0,00022
Metacore Development_Mu-type opioid receptor signaling via Beta-arrestin 0,00032
Metacore Immune response_PGE2 signaling in immune response 0,00038
Metacore Development_S1P2 and S1P3 receptors in cell proliferation and differentiation 0,00055
KEGG ECM-receptor interaction 0,009
doi:10.1371/journal.pone.0035423.t003
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Figure 2. Signature validation of miRNA-mRNA and proteins found differentially expressed between 402-91/ET and 402-91 cell
line. Panel A. qRT-PCR and Western blot analysis showing differences in the expression levels of let-7e and its downstream targets (CCDN1, E2F5,
SEMA4C, HMGA1 and HMGA2). Panel B. qRT-PCR and Western blot for miR-21 and its downstream target, PDCD4. qRT-PCR data are the mean of
three independent experiments performed in triplicate and calculated with the 22DDCt method as described in the material and method section. The
control 402-91 cells values are arbitrarily set as 1. Bars are +/2 SD. * is significant with p,0.05, ** p,0.01, ***p,0.001, as assessed with Student T-
test. Western blot is representative of at least two independent experiments.
doi:10.1371/journal.pone.0035423.g002
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MetaCore analysis showed a prevalence of apoptosis-survival
related functions for the upregulated proteins: the top three
categories from enrichment analysis on GO terms showed
prevalence of terms associated to cell death (p,0.0001). Of the
top three pathways, two were associated with apoptosis (FAS
signaling cascades and TNF family pathways), and ‘‘death domain
receptors and caspases in apoptosis’’ was identified as significantly
enriched in process networks. On the other hand, GO terms over-
represented in downregulated proteins mainly involved cellular
component reorganization and affected pathways and networks
including AKT signaling, cytoskeleton remodeling and G1/S cell
cycle regulation (Table 4). Other involved functions were related
to cell cycle, cytoskeletal remodeling and growth factor regulation.
Likewise, the analysis performed with DAVID identified among
the highest significant results pathways related to apoptosis, stress
induction of HSP and the p53 pathway for upregulated proteins,
and cell cycle, AKT signaling, and FAS signaling for downreg-
ulated proteins (Table 4).
CHOP transcription factor binding site analysis
It has been reported that FUS-CHOP is the main molecular
target of trabectedin in myxoid liposarcoma cell line [12,13].
Under the assumption that the FUS-CHOP binding site is the
same of CHOP (then of the heterodimer CHOP-C/EBPa´), we
tried to identify putative miRNAs transcriptionally regulated by
the chimera and therefore having an enriched CHOP motif in
their promoter regions.
Transcription factor binding sites enrichment analysis per-
formed on separately up or downregulated genes (oPOSSUM web
tool with Z-score.5 and p-value,0.5) identified respectively 10
and 11 binding sites enriched (see Table S5). CHOP binding site
was not identified as enriched.
The identification of miRNA promoter regions is still a
challenging task, since putative miRNA regulatory regions could
be several thousands of bp upstream of the pri-miR. There are
only a limited number of experimentally validated miRNA
promoters. In particular only few of the differentially expressed
miRNAs have an experimentally validated promoter region. In
this context, TFBS enrichment analysis on the promoter regions of
the differentially expressed miRNAs would be misleading.
However, we could identify miRNAs among those differentially
expressed with an experimentally validated promoter with a
putative CHOP binding site. Using mirGen2.0 web tool, we found
that miR-130a (downregulated in 402-91/ET cell line) and miR-
21 (upregulated in 402-91/ET cell line) have a CHOP-C/EBPa´
binding site in their experimentally validated promoter regions,
while using CircuiDB database [29] we found that miR-7
(upregulated in 402-91/ET cell line) has a CHOP-C/EBPa´
binding site in its computationally identified promoter region.
Integrative analysis and network reconstruction
Integration of miRNA and mRNA expression
data. miRNA effect on mRNA degradation can be detected
by the anti-correlation relationship between miRNA and gene
expression. To reconstruct miRNA-mRNA network in this section
we focused only on miRNAs having an inverse relationship with
their respective mRNA targets.
Using only the list of differentially expressed miRNAs and genes
we reconstructed the network in which nodes represent both genes
and miRNAs (colored according to their expression levels) while
edges represent computationally identified miRNA-target interac-
tions. The entire resulting network is available in Figure S1 and
Table S6.
We then focused on specific network modules (sub-networks),
corresponding to pathways or specific miRNAs found to be
interesting according to the biological problem under study
(Figure 4). In particular we selected genes involved in negative
regulation of apoptosis (Figure 4A) and cell cycle (Figure 4B).
Figure 3. Heat map and cluster analysis of the 336 differen-
tially expressed proteins between resistant and sensitive cell
lines. Red and green represent respectively differentially upregulated
and downregulated proteins in 402-91/ET cell lines.
doi:10.1371/journal.pone.0035423.g003
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Then we selected the putative targets of those miRNAs (miR-7,
miR-21 and miR-130a) with experimentally validated or compu-
tationally identified CHOP- C/EBPa´ binding sites in their
promoter regions (Figure 5). Several miRNAs and genes
identified as differentially expressed have been validated in qRT-
PCR as previously reported (Figure 2; Table S2).
Integration of miRNA-protein expression levels. As the
effect of miRNAs does not limit to mRNA degradation but also
translational repression, we integrated miRNA and protein
expression using the approach described previously (see above).
As apoptosis and cell cycle were mainly involved in trabectedin
resistance as reported in the previous enrichment results (see
Table 4), we generated a miRNA-protein network for these two
pathways (Figure 6, panels A and B respectively).
Integration of mRNA and protein levels. The
simultaneous analysis of differentially expressed genes and
proteins showed a core of 22 genes for which not only the
mRNA expression but also the protein levels were significantly
altered between 402-91/ET and 402-91 cell lines. Within this core
it is possible to clearly identify two sets of genes: 54% of genes with
mRNA positively correlated with protein levels (r = 0.96) and 45%
Table 4. Gene Ontology categories and KEGG, PANTHER and Metacore pathway enrichment analysis within up and down
regulated proteins.
Category Name p-value
Expression 402-91/
ET vs 402-91
GeneOntology
GO apoptosis 0,00000 up
GO programmedcelldeath 0,00000 up
GO celldeath 0,00000 up
GO cellular component organization 0,00000 down
GO cellular component organization or biogenesis 0,00000 down
GO cellular component organization at cellular level 0,00000 down
Pathway
KEGG hsa04115:p53 signalingpathway 0,00027 up
KEGG hsa04210:Apoptosis 0,00140 up
KEGG hsa05219:Bladder cancer 0,00397 up
KEGG hsa05218:Melanoma 0,04945 up
KEGG hsa05212:Pancreatic cancer 0,05277 up
KEGG hsa04010:MAPK signalingpathway 0,07292 up
KEGG hsa05200:Pathways in cancer 0,07840 up
KEGG hsa04650:Natural killer cell mediated cytotoxicity 0,14232 up
PANTHER P00006:Apoptosis signalingpathway 0,00052 up
PANTHER P00059:p53 pathway 0,01579 up
Metacore Apoptosis and survival_p53-dependent apoptosis 0 up
Metacore Apoptosis_Death Domain receptors &caspases in apoptosis 0 up
Metacore Cell adhesion_Amyloid proteins 0 up
Metacore Cell cycle_G1-S Growth factor regulation 0,00001 up
Metacore Apoptosis and survival_Role of IAP-proteins in apoptosis 0,00026 up
Metacore Translation _Regulation of EIF2 activity 0,00084 up
KEGG hsa04110:Cell cycle 0,00000 down
KEGG hsa05200:Pathways in cancer 0,00235 down
KEGG hsa04510:Focal adhesion 0,00681 down
KEGG hsa04210:Apoptosis 0,01537 down
KEGG hsa05212:Pancreatic cancer 0,03870 down
PANTHER P00006:Apoptosis signalingpathway 0,00022 down
PANTHER P00020:FAS signalingpathway 0,00130 down
Metacore Cytoskeleton remodeling_TGF, WNT and cytoskeletal remodeling 0,00000 down
Metacore Signaltransduction_AKTsignaling 0,00000 down
Metacore Cytoskeletonremodeling_Cytoskeletonremodeling 0,00000 down
Metacore Cell cycle_G1-S Growth factor regulation 0,00000 down
Metacore Cell cycle_G1-S Interleukin regulation 0,00001 down
Metacore Cell cycle_Core 0,00015 down
doi:10.1371/journal.pone.0035423.t004
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Figure 4. Post-transcriptional network. miRNA and mRNA subnetworks representing negative regulation of apoptosis (Panel A) and cell cycle
(Panel B). Small circle: differentially expressed genes found by microarray analysis. Big circle: differentially expressed genes validated by qRT-PCR.
Square: differentially expressed genes encoding a protein found differentially expressed using protein array. Exagon: differentially expressed genes
validated with qRT-PCR encoding a protein found differentially expressed using protein array. Small diamonds: differentially expressed miRNAs found
by array analysis. Big diamonds: differentially expressed miRNAs validated by RT-PCR. Filled colors inside represent gene expression, border colors
outside represent protein level.
doi:10.1371/journal.pone.0035423.g004
Trabectedin Resistance in Myxoid Liposarcoma
PLoS ONE | www.plosone.org 11 April 2012 | Volume 7 | Issue 4 | e35423
of genes with mRNA negatively correlated with protein levels
(r =20.6).
This result can be easily explained considering two points: i.
mRNA and protein levels are not quantified from exactly the same
biological sample but rather from two different biological
replicates ii. mRNAs and proteins have different turnover.
Integration of miRNA-mRNA-protein expression
levels. miRNA, mRNA and protein can be combined in
modules in which a miRNA acts on messenger targets and the
resultant effect is measured on the protein.
In our study the combination of post-transcriptional and pre-
translational regulatory networks allows the identification of
triplets (miRNA-mRNA-protein) representing different miRNA
action scenarios. Mapping the levels of expression on these
modules allows us to identify putative different types of regulatory
loops [32]. The possible loops to be considered regard i) an up/
down miRNA regulating the target mRNA through degradation
(type A, Figure 7A), ii) an up/down miRNA regulating the
protein level through translational repression (type B, Figure 7B),
iii) an up/down miRNA whose expression does not support an
action on the predicted targets or an up/down miRNA whose
effect is not sufficient to overcome the effect of another external
signal (and thus is impossible to hypothesize if miRNA acts as
mRNA degradation or translational repressor) (type C,
Figure 7C).
Depending on the signal, loops can be divided into two classes:
coherent (loop of type A; characterized by mutually exclusive
expression between miRNA and its targets) and incoherent (loops
of type B and C; characterized by coexpression of miRNA and its
Figure 5. Target genes shared by miR-7, miR-21 and miR-130a. Nodes represent miRNAs and mRNA gene expression. Red represents gene/
miRNA upregulation, green downregulation.
doi:10.1371/journal.pone.0035423.g005
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target) [33]. In the coherent loops both pathways from the signal
to the target have the same effect (both repressing or activating
target expression), while in the incoherent ones the two pathways
have opposite effects [33]. From a biological point of view,
incoherent loops of type B have an easy interpretation while
incoherent loops of type C have a less clear explanation and then
usually require further investigations. Figure 7 shows in details
these possibilities jointly with the loops found in our data. In
particular we found 38 putative loops of type A, 34 of type B and
28 of type C. Looking at the coherent loops, we identified 3 loops
involving differentially expressed miRNAs with roles in drug
resistance and/or potentially regulated by FUS-CHOP chimera
Figure 6. Pre-translational network. miRNA and protein subnetworks representing apoptosis (Panel A) and cell cycle (Panel B). Small
circle: differentially expressed genes found by microarray analysis. Square: differentially expressed genes encoding a protein found differentially
expressed using protein array. Exagon: differentially expressed genes validated with qRT-PCRencoding a protein found differentially expressed using
protein array. Small diamonds: differentially expressed miRNAs found by array analysis. Big diamonds: differentially expressed miRNAs validated by
qRT-PCR. Filled colors inside represent gene expression, border colors outside represent protein level.
doi:10.1371/journal.pone.0035423.g006
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(let-7e, miR-130a, miR-98 and miR-7). These loops have as
potential targets MDC1, TNFRSF21 (overexpressed in 402-91/
ET), BACE1 and BAP1 (underexpressed in 402-91/ET). MDC1
activates the intra-S phase and G2/M phase cell cycle checkpoints,
in response to DNA damage. It has been demonstrated that
MDC1 is implicated in cellular apoptotic response [33].
TNFRSF21 encodes a protein that is a member of the TNF-
receptor superfamily. This receptor has been shown to activate
NF-kappaB and MAPK8/JNK and induce cell apoptosis. The
protein encoded by BAP1 localizes to the nucleus and it interacts
with the RING finger domain of the breast cancer 1, early onset
protein (BRCA1). This gene is thought to be a tumor suppressor
gene that functions in the DNA repair. As far as the incoherent
circuits of type B concerns we identified two loops with miR-130a
that have PRKD1 and TNF as potential targets and one loop
regarding a cluster of miRNAs (miR-320) with TNFRSF21. On
the other hand, as far as circuits of type C concerns we identified 3
loops with let-7e and miR-98, FXR2, TUBB4 genes and
maintenance of genomic stability pathway.
Figure 7. Regulatory loops identified through the combination of miRNA, mRNA and protein expression levels. Panel A. Coherent
regulatory loops: up/down miRNA regulating the target mRNA through degradation. Panel B. Incoherent regulatory loops: an up/down miRNA
regulating the protein level through translational repression. Panel C. Incoherent regulatory loops: an up/down miRNA whose effect is not sufficient
to overcome the effect of another external signal and thus it is impossible to hypothesize if miRNA acts as mRNA degradation or translational
repressor.
doi:10.1371/journal.pone.0035423.g007
Trabectedin Resistance in Myxoid Liposarcoma
PLoS ONE | www.plosone.org 14 April 2012 | Volume 7 | Issue 4 | e35423
Discussion
Despite its complex molecular heterogeneity, cancer results
from the integration of at least ten common pathways that drive
tumor progression and therapy response [34]. It is now becoming
clear that pathway integration rather than single gene manipula-
tion could represent the basis to understand malignant transfor-
mation and therapy response.
Based on this hypothesis, in the current study we exploited
different transcriptomic (miRNA and GE array) and proteomic
(protein array) platforms to generate, in a well defined in vitro
model of tumor cells, an integration map of the key pathways
possibly involved in the mechanism of resistance to trabectedin.
In this perspective, our study is one of the first attempts towards
the combination of the three layers of gene regulation (transcrip-
tional, post-transcriptional and translational) for the identification
of those pathways and networks playing a critical role in
trabectedin action.
In particular, in this work, we looked for changes in molecular
behavior due to an intensive and prolonged treatment with
trabectedin that was performed to induce drug resistance. Then,
using a systems biology approach we systematically screened the
possible sources of variability in mRNAs, miRNAs and protein
expressions. Our integration strategy started by extracting
individual results from the three different layers and then
combining them to increase their power.
Gene expression data
Regarding gene expression data, a significant portion of the
underexpressed (6%) and overexpressed (2%) genes are zinc finger
(ZF) proteins. ZF proteins are multiple and play important role in
the metabolism of normal cells. There are many reports on the
inhibition of ZF transcription factors in early as well as advanced
stages of oncogenesis, including the impairment of signal
transduction [35]. These results are also in agreement with the
recent findings of Duan et al. [36] who performed gene expression
analysis on chondrosarcoma cell lines resistant to trabectedin.
Remarkably, the authors found some ZF proteins to be
differentially expressed and suggest that ZF proteins are involved
in the mechanism of trabectedin resistance. However, differently
from Duan et al. [36] we did not find overexpression of ZNF93
and ZNF43 in the resistant 402-91/ET cell line.
Interestingly, we found BIRC2 (which encodes for c-IAP1
protein) overexpressed in 402-91/ET cells. c-IAP1 inhibits
apoptosis by binding to TNF receptor-associated factors TRAF1
(that we found overexpressed in resistant cells) and TRAF2. It has
recently been reported that BIRC2 is associated with resistance of
esophageal squamous cell carcinomas to drug-induced apoptosis
[37] and that c-IAP1 could be a novel predictive marker for
resistance to radiotherapy in cervical squamous cell carcinomas
[37].
The 402-91/ET cell line seems to be characterized by a reduced
apoptosis and an increased cell proliferation. It is noteworthy that
pathways involved in cell adhesion are enriched in downregulated
genes, suggesting a loss of 402-91/ET intracellular communica-
tions and altered cellular processes such as proliferation, migration
and differentiation.
miRNA expression data
miRNAs are involved in processes such as development,
carcinogenesis, cell survival, and apoptosis, as well as cellular
sensitivity to anticancer drugs [38]. However, opposite effects can
be seen towards the same compound in different tumor types,
suggesting a complex relationship between miRNAs and drug
resistance [39].
Among differentially expressed miRNAs in 402-91/ET we
found miR-21, let-7e, miR-192, miR-130a and miR-98, whose
ability to affect the potencies of a number of anticancer agents
have been recently reported. Several studies recently reported a
relation between the overexpression of miR-21 and the resistance
to a variety of anticancer drugs. In particular, Shi and colleagues
[40] demonstrated a role of miR-21 in temozolomide resistance in
glioblastoma cells. Moreover, the overexpression of miR-21 has
also been found to induce resistance against cytosine arabinoside
(Ara-C) and arsenic trioxide. Targeting of PDCD4 (under-
expressed in 402-91/ET cells) by miR-21 prevented Ara-C-
induced apoptosis in the leukemic HL60 cell line [41], whereas in
several myelogenous cell lines reduced expression of PDCD4 by
miR-21 targeting prevented arsenic trioxide-induced apoptosis
[42].
Let-7e, and miR-130a were found underexpressed in a panel of
paclitaxel- and cisplatin-resistant cells lines [43]. Furthermore,
Herbert et al. [44] predicted HGMA2 (overexpressed in micro-
array and validated with qRT-PCR) as a target for miR-98, and
showed their involvement in promotion of resistance to doxoru-
bicin and cisplatin, while Boni and colleagues suggested a role of
miR-192 in 5-fluorouracil resistance in colorectal cancer [45].
In general, pathway analysis on microRNA target genes
highlights a subset of the pathways previously found in gene
expression analysis. This means that in some specific pathways
both levels of transcription are co-involved in the development of
resistance to trabectedin. Cell cycle, angiogenesis, regulation of
transcription and apoptosis-survival are the mostly over-represent-
ed pathways.
CHOP transcription factor binding site
We investigated the presence of differentially expressed
miRNAs, potentially transcriptionally regulated by FUS-CHOP
chimera with an enriched CHOP motif in their promoter regions.
We found three differentially expressed miRNAs (miR-21, miR-
130a, miR-7) having either computationally or experimentally
validated CHOP binding sites. Remarkably two of them, miR-21
and miR-130a, were previously discussed because of their
documented involvement in drug resistance.
Among our differentially expressed genes we found 149 putative
targets of miR-7 (with an anti-correlated expression profile), which
are mainly involved in cell cycle, chromatin and cytoskeleton
organization. Among them we found PIK3CD, RB1, CAMK2D,
CUL5. There are emerging evidences about the involvement of
PI3K signaling cascade in myxoid liposarcoma. The overexpres-
sion of receptor tyrosine kinases MET, IGF1R and IGF2 promote
cell survival through both the PI3K/Akt and the Ras-Raf-ERK/
MAPK pathways [46].
Mir-21 had 99 putative anti-correlated targets mostly involved
in the regulation of transcription (CBX4, KLF13, PDCD4 and
several ZF proteins).
Among the 118 anti-correlated putative targets of miR-130a, we
identified genes involved in vasculature development (ROBO4,
SIPR1, NRP1, ELK3, EDN1, THBS1) and cell motion, in
particular FOSL1, PLCL2 and LYN. FOSL1 dimerizes with
proteins of the JUN family (JUNB is overexpressed in resistant cell
line) forming the transcription factor complex AP-1; FOS proteins
have been implicated as regulators of cell proliferation, differen-
tiation, and transformation. Furthermore, LYN has been recently
shown to act as a mediator of tumor invasion.
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Antibody array data
Gene and miRNA expression profiles are able to separate 402-
91/ET from 402-91 cell lines (Figure 1A and 1B), while protein
expression dendrogram (Figure 3) has a more heterogeneous
behaviour. 402-91 cell line is divided into two groups; one 402-91/
ET sample clusters with 402-91 ones. It is much more difficult to
quantify protein expression than gene expression in a multiplex
manner than for gene expression, due to the larger variability in
the physico-chemical properties of proteins [31]. Therefore, this
discrepancy could be due to the higher variability of protein arrays
than that of mRNA and miRNA assessment.
GO enrichment analysis on differentially expressed proteins
seems to be much more focused than the same analysis on genes.
In particular, apoptosis-survival and cell cycle are categories
capable of collecting the greatest number of differences between
sensitive and resistant cells. Among the over-represented pathways
we found p53, apoptosis and MAPK.
In particular we found CCND1, CCND2, BBC3, CDKN2A,
PERP involved in p53 signaling, RB1, E2F2, E2F3, E2F4,
SMAD4, CDC14, CDC25A, CDC6, CDC7 involved in cell cycle.
Some of these proteins are involved in the regulation of
transcription in G1/S phase of the mitotic cell cycle. G1/S
transition is a rate-limiting step in cell cycle progression [47].
The cyclin D1 proto-oncogene is a key regulator of G1 to S
phase progression in several cell types. Together with CDK4 and
CDK6, cyclin D1 forms active complexes that promote cell cycle
progression by phosphorylating and inactivating the retinoblasto-
ma protein (RB1). RB1 in turn leads to the release of the E2F
family of transcription factors driving the expression of several
genes associated with S phase progression [48]. A number of
therapeutic agents have been observed to induce cyclin D1
degradation in vitro, indicating that such an induction may offer a
useful avenue for therapeutic intervention.
Integrative analysis and network reconstruction
After the analysis and the discussion of each regulatory aspect
(mRNAs, miRNAs and proteins) separately, we combined all the
biological evidences within a systems biology approach in order to
have a wider perspective of the regulatory phenomena acting
during trabectedin resistance.
miRNAs act as post-transcriptional regulators of gene expres-
sion. The reduction of protein levels is the final result of the
regulation that can be achieved through two strategies: (i) mRNA
degradation or (ii) translational repression. The effects of the two
modes of action can be evaluated at different points of the
transcription-translation pathway. Focusing on the two main
highly correlated pathways that seem to be involved in trabectedin
resistance (negative regulation of apoptosis and cell cycle), we
reconstructed two different networks: i) the network composed of
differentially expressed mRNAs targeted by differentially ex-
pressed miRNAs that allow us to study the regulation at the
transcriptional level, hereafter the ‘‘post-transcriptional regulatory
network’’ and ii) the network composed by differentially expressed
miRNAs leading to differentially expressed proteins, hereafter
‘‘pre-translational regulatory network’’.
It is clear the central role that CCND1, RB1, E2F4, TNF,
CDKN1C, ABL1, TNFRSF21 play in both post-transcriptional
and pre-translational regulatory networks. In particular, they act
as a bridge between the two parts of the network with opposite
regulations: upregulated genes/protein and downregulated
miRNA and downregulated genes/protein and upregulated
miRNA.
In some cases the involvement of miRNAs can explain the
discordant relation between the transcriptome and the proteome.
In a seminal review Inui et al. [32] describe the role of miRNAs in
pathways as decision maker elements to discriminate real versus
too weak or too transient signals. In this study we identified 3 loops
involving differentially expressed miRNAs with roles in drug
resistance; these loops have as potential targets MDC1 (overex-
pressed in 402-91/ET), BACE1 and BAP1 (underexpressed in
402-91/ET).
Concluding remarks
The present study is one of the first works that try to screen the
behavior of genes, microRNAs (miRNAs) and proteins in order to
reconstruct in silico the regulatory networks leading to resistance to
anticancer agents such as trabectedin. Diverse sources of omic data
have been used to describe altered regulatory mechanisms within a
transcriptional, post-transcriptional and translational perspective.
The combination of the three layers of regulation gave us the
possibility to reconstruct putative gene-miRNA-protein circuits
altered in trabectedin resistance. We found that transcriptome and
proteome data agreed in recognizing anti-apoptosis and cell cycle
proliferation as the two main biological processes characterizing
the difference between 402-91 and 402-91/ET cell lines. All the
hallmarks of cancer seem to be altered in the resistant cell line,
raising the hypothesis that the mechanism of resistance is acting
with more strength on the same molecular markers triggered by
cancer development.
On the other hand, post-transcriptional analysis revealed two
miRNAs (miR-21 and miR-130a) already identified as playing a
role in drug resistance and putatively regulated by the FUS-
CHOP chimera, which could be good markers for future
functional studies. Most of miR-21 and miR-130a targets are
known oncogenes or oncosuppressors highlighting their involve-
ment in malignancies.
Once validated on in vivo models this approach might allow the
identification of druggable targets for trabectedin-resistant malig-
nancies.
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Figure S1 miRNA and mRNA network reconstruction using
mirSVR as target prediction tool. Colors represent expression
(green and red for under and overexpressed genes, light green and
light red for under and overexpressed miRNA) and edges between
miRNA and gene represent mirSVR predictions, while gene-gene
edges represent validated gene-gene interactions from KEGG
database.
(PDF)
Table S1 Complete list of probes identifying differentially
expressed genes.
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sites enriched in the promoter region of up and downregulated
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